Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hydrobromide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Hydrobromide. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-003216-28 Sponsor Protocol Number: A6531002 Start Date*: 2020-09-10
    Sponsor Name:Pfizer, Inc.
    Full Title: A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP PILOT STUDY TO EVALUATE THE EFFICACY OF DEXTROMETHORPHAN HYDROBROMIDE ON ACUTE COUGH IN A PEDIATRIC POPULATION
    Medical condition: cough
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001339-38 Sponsor Protocol Number: 17-AVP-786-305 Start Date*: 2018-01-22
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/qui...
    Medical condition: Agitation Associated with Dementia of the Alzheimer's Type
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10001497 Agitation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) FR (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001836-69 Sponsor Protocol Number: Vort-MCI_001 Start Date*: 2021-09-17
    Sponsor Name:Medical University of Vienna
    Full Title: Effects of Vortioxetine in Mild Cognitive Impairment measured by Functional Magnetic Resonance Imaging
    Medical condition: Mild cognitive impairment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001352-33 Sponsor Protocol Number: 18-AVP-786-207 Start Date*: 2021-09-10
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-arm study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfa...
    Medical condition: Negative symptoms of schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) PL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002455-29 Sponsor Protocol Number: 15-AVP-786-303 Start Date*: 2018-07-31
    Sponsor Name:Avanir Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Long-term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the Treatment of Agitation...
    Medical condition: Agitation Associated with Dementia of the Alzheimer's Type
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10001497 Agitation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) FR (Completed) PL (Completed) BG (Completed) CZ (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001212-30 Sponsor Protocol Number: ECEP-BPD Start Date*: 2018-09-18
    Sponsor Name:Central Institute of Mental Health, represented by commercial and administrative Director
    Full Title: A trial to study effects of a single dose Citalopram on emotion processing in female patients with Borderline Personality Disorder and the associated modulation of fMRI BOLD signals
    Medical condition: Borderline Personality Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10006034 Borderline personality disorder PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003671-35 Sponsor Protocol Number: SPR994-301 Start Date*: 2019-04-18
    Sponsor Name:Spero Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) ...
    Medical condition: complicated urinary tract infection or acute pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10046571 Urinary tract infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) BG (Completed) HU (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-003112-39 Sponsor Protocol Number: NUIG-2017-002 Start Date*: 2020-01-08
    Sponsor Name:National University of ireland Galway
    Full Title: A Randomised Double-Blinded Placebo-Controlled Trial to Assess the Efficacy and Safety of Scopolamine Compared to Placebo in Individuals with Bipolar Disorder who are Experiencing a Depressive Epis...
    Medical condition: Bipolar Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10004937 Bipolar disorder NEC LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005472-27 Sponsor Protocol Number: 70639 Start Date*: 2009-03-30
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Die antidementive Therapie mit Acetylcholinesteraseinhibitoren: Untersuchung von Plasmakonzentrationen, Arzneimittelinteraktionen und Therapieeffekt in Abhängigkeit von genetischen Polymorphismen
    Medical condition: Anhand der vorliegenden Studie soll untersucht werden, ob genetische Polymorphismen im CYP2D6-, im MDR1- oder im ACHE Gen mit sub- bzw. supratherapeutischen Wirkstoffspiegeln im Plasma, mit relevan...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022257-41 Sponsor Protocol Number: Lu AA21004/CCT-002 Start Date*: 2010-12-07
    Sponsor Name:Takeda Global Research and Development Centre (Europe) Ltd.
    Full Title: A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients with Major Depressive Disorder
    Medical condition: major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025454 Major depressive disorder, recurrent episode LLT
    12.1 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) FI (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-000798-26 Sponsor Protocol Number: 20-AVP-786-306 Start Date*: 2021-06-22
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q...
    Medical condition: Agitation in patients with dementia of the Alzheimer’s type
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10001499 Agitation mental LLT
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) BG (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006020-20 Sponsor Protocol Number: 015K-CL-RA22 Start Date*: 2012-09-07
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004859 10042952 Systemic rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-001955-11 Sponsor Protocol Number: AP105162012 Start Date*: 2013-12-26
    Sponsor Name:Psicofundación. Fundación Española para Promoción, Desarrollo Científico y Profesional de la Psicología
    Full Title: A pilot study to treat emotional disorders in Primary Care with evidence-based psychological techniques: A randomized controlled trial
    Medical condition: Emotional disorders specified as anxiety disorders (e.g., panic disorder, generalized anxiety disorder, social phobia, specific phobia), mood disorders (e.g., major depressive disorder, dysthymia),...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013689-18 Sponsor Protocol Number: GALALZ4041 Start Date*: 2010-05-11
    Sponsor Name:Janssen-Cilag S.A.
    Full Title: ESTUDIO FASE IV PARA LA EVALUACIÓN DEL EFECTO MODULADOR DE LA GALANTAMINA (REMINYL CLP®) SOBRE EL RITMO CIRCADIANO DE PACIENTES CON ENFERMEDAD DE ALZHEIMER MODERADA
    Medical condition: Enfermedad de Alzheimer
    Disease: Version SOC Term Classification Code Term Level
    11 10012271 Demencia de tipo Alzheimer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002178-22 Sponsor Protocol Number: 11-AVR-130 Start Date*: 2011-12-26
    Sponsor Name:Avanir Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in ...
    Medical condition: Central Neuropathic Pain in Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004174-34 Sponsor Protocol Number: Citalopram2017 Start Date*: 2018-04-10
    Sponsor Name:Targid, KU Leuven
    Full Title: A placebo-controlled trial with citalopram for the treatment of typical reflux symptoms in patients with reflux hypersensitivity or functional heartburn with incomplete proton pump inhibitor response
    Medical condition: Functional heartburn and reflux hypersensitivity with incomplete respons to proton pomp inhibitors
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006018-15 Sponsor Protocol Number: 015K-CL-RA21 Start Date*: 2012-07-28
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004859 10042952 Systemic rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PL (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-000841-12 Sponsor Protocol Number: 215.1364 Start Date*: Information not available in EudraCT
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomised open label, six way, cross-over scintigraphic evaluation of the effect of inspiratory flow rate on lung and oropharyngeal deposition with the Respimat(R) inhaler vs a Metered Dose Inha...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD) is characterised by airflow limitation and bronchial inflammation. Clinically, COPD is characterised by progressive dyspnoea on exertion and intermitten...
    Disease: Version SOC Term Classification Code Term Level
    8.0 10010952 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000905-31 Sponsor Protocol Number: 11492C Start Date*: 2007-05-03
    Sponsor Name:H. Lundbeck A/S
    Full Title: A long term open label, flexiable dose, extension study evaluationg the safety and tolerability of Lu AA21004 in patients with Major Depressive Disorder
    Medical condition: Indication: Major Depressive Disorder according to the DSM-IV-TR
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009710 CNS depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) SE (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-016300-23 Sponsor Protocol Number: RAA 2009-007 Start Date*: 2009-12-14
    Sponsor Name:King's College London
    Full Title: Pilot double blind randomised placebo controlled crossover trial of Hyoscine for the treatment of Clozapine induced nocturnal sialorrhoea.
    Medical condition: Sialorrhoea in patients treated with clozapine.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10059812 Sialorrhoea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 01 08:39:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA